R&D Spending Showdown: Eli Lilly and Company vs PTC Therapeutics, Inc.

Eli Lilly vs. PTC: A Decade of R&D Investment

__timestampEli Lilly and CompanyPTC Therapeutics, Inc.
Wednesday, January 1, 2014473360000079838000
Thursday, January 1, 20154796400000121816000
Friday, January 1, 20165243900000117633000
Sunday, January 1, 20175281800000117456000
Monday, January 1, 20185051200000171984000
Tuesday, January 1, 20195595000000257452000
Wednesday, January 1, 20206085700000477643000
Friday, January 1, 20217025900000540684000
Saturday, January 1, 20227190800000651496000
Sunday, January 1, 20239313400000666563000
Monday, January 1, 202414271000000
Loading chart...

Igniting the spark of knowledge

R&D Spending: A Tale of Two Innovators

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Eli Lilly and Company and PTC Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Eli Lilly's R&D expenses surged by nearly 97%, peaking at over $9.3 billion in 2023. This reflects a robust strategy to maintain its leadership in the industry. In contrast, PTC Therapeutics, Inc. has shown a more modest increase of approximately 735% in the same period, reaching $666 million in 2023. While Eli Lilly's spending dwarfs that of PTC, the latter's growth rate is impressive, highlighting its aggressive push to expand its research capabilities. This spending showdown underscores the diverse strategies companies employ to drive innovation and secure their future in the pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025